← Research status explorer
Peak / Growth axis
CJC-1295
Current research status
Human Research
Early/historical clinical research
Preclinical
Human Research
Overview
CJC-1295 is a modified GHRH analogue studied in early-phase human pharmacology trials evaluating its ability to raise growth hormone and IGF-1 levels. It has been administered to humans in published research, but has not been advanced through a conventional sponsor-run Phase 1–3 program to an approved product.
Sources
Last reviewed: September 2026
